These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 21426843

  • 1. [Clinicopathologic features of retinoblastoma and expression of VEGF and Ki-67 after comprehensive treatment].
    Xue K, Qian J, Bi YW, Yao YQ, Yuan YF, DA CD.
    Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):134-41. PubMed ID: 21426843
    [Abstract] [Full Text] [Related]

  • 2. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
    Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO.
    Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Management and outcome of retinoblastoma with vitreous seeds.
    Manjandavida FP, Honavar SG, Reddy VA, Khanna R.
    Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Retinoblastoma regression patterns and results following chemo reduction and adjuvant therapy].
    Xue K, Qian J, Yue H, Yuan YF, Zhang R.
    Zhonghua Yan Ke Za Zhi; 2012 Jul; 48(7):625-30. PubMed ID: 22943868
    [Abstract] [Full Text] [Related]

  • 8. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma.
    Shields CL, Kaliki S, Shah SU, Bianciotto CG, Liu D, Jabbour P, Griffin GC, Shields JA.
    Ophthalmology; 2012 Jan; 119(1):188-92. PubMed ID: 21975042
    [Abstract] [Full Text] [Related]

  • 9. Cavitary changes in retinoblastoma: relationship to chemoresistance.
    Mashayekhi A, Shields CL, Eagle RC, Shields JA.
    Ophthalmology; 2005 Jun; 112(6):1145-50. PubMed ID: 15885779
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.
    Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B, Chan HS, Gallie BL.
    J Clin Oncol; 2011 Mar 01; 29(7):845-51. PubMed ID: 21282531
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
    Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA.
    JAMA Ophthalmol; 2014 Mar 01; 132(3):319-25. PubMed ID: 24407202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
    Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, Shields JA.
    Ophthalmology; 2009 Mar 01; 116(3):544-551.e1. PubMed ID: 19157557
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.